TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05965414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS6253 Solution for Injection
Description: Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline solution for intra-venous injection
Study: NCT06147674

Intervention type: DEVICE
Intervention: VQm Pulmonary Health Monitor™
Description: The VQm Pulmonary Health Monitor™ (may be referred to as the VQm PHM™) is a a Class IIa, Health Canada approved medical device used as an adjunct monitor and is non-life supporting, providing clinicians with measurements of pulmonary function parameters of mechanically ventilated adult patients. The measurements provided are:~* Pulmonary Blood Flow (PBF)~* Shunt Fraction (Qsi)~* Dead space (VD):~* Functional Residual Capacity (FRC)
Study: NCT06550921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation of oligometastasis
Description: The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
Study: NCT06080126

Intervention type: OTHER
Group type: OTHER
Intervention: Control: per usual practice
Description: 160 patients were included as per usual practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention MAF
Description: 160 patients were included with MAF intervention.
Study: NCT04640116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation (MWA)
Description: MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
Study: NCT06458270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt warning label
Description: A salt warning label will feature on the restaurant menu next to menu items that are high in salt (\>3g, more than 50% of guideline daily amount \[GDA\] in the UK).
Study: NCT05545501

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Salt, No β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Salt, No β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Salt, High β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
Study: NCT05974332

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oncostatin M
Description: Test to diagnosis of Ulcerative colitis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oncostatin M
Description: Test to diagnosis of Ulcerative colitis
Study: NCT06144372

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroconductive and Electrohydraulic types
Description: The patients were randomly assigned to two types of lithotripter.

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroconductive and Electrohydraulic types
Description: The patients were randomly assigned to two types of lithotripter.
Study: NCT06181149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delaying speech initiation
Description: This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory errors and pre-speech auditory modulation
Description: This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contributions of the speech premotor cortex to pre-speech auditory modulation
Description: This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delaying auditory feedback
Description: This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
Study: NCT04725669

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ELISA IgG Testkit
Description: All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
Study: NCT05719961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection
Description: Part I: A single dose of 1.2noml/kg is administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Part I: A single dose of 0.2U/kg is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20014 injection
Description: Part II: Ascending single doses at three dose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 30 Injection
Description: Part II: A single dosewas administered
Study: NCT04814641

Intervention type: BIOLOGICAL
Intervention: hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit
Description: Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.

Intervention type: BIOLOGICAL
Intervention: hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit
Description: Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
Study: NCT05912101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group Block
Description: A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprainguinal Fascia Compartment Block
Description: A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-1 Block
Description: A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
Study: NCT05854095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pivot Bridge
Description: transcatheter for short-term treat Functional Tricuspid regurgitation
Study: NCT05019677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+PD-1+Tight
Description: Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W
Study: NCT06305845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital crowns
Description: crowns fabricated digitally by CAD-CAM technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zirconia crowns
Description: crowns that are ready made for primary teeth
Study: NCT06060470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based dance group
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control
Description: Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
Study: NCT06274827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superficial Electromyography
Description: For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
Study: NCT06550323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using virtual reality glasses
Description: Group using virtual reality glasses: During the procedure, individuals will wear glasses.
Study: NCT05786313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centerpiece titanium plate
Description: All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Centerpiece titanium plate
Description: All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
Study: NCT05991375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXmedetomidine
Description: 28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
Study: NCT05767385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Arm
Description: * Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline.
Study: NCT05928351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program (SPP)
Description: The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Program (SPP)
Description: The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
Study: NCT05767385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neonatal Neurobehavioral Scale
Description: Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.
Study: NCT05110664

Intervention type: DRUG
Intervention: PYY (3-36) Peptide
Description: oral PYY3-36 solution

Intervention type: DRUG
Intervention: PYY (3-36) Peptide
Description: oral PYY3-36 solution

Intervention type: DRUG
Intervention: Placibo
Description: oral placebo solution

Intervention type: DRUG
Intervention: Placibo
Description: oral placebo solution
Study: NCT05733910

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: simultaneous integrated boost of carbon ions radiation therapy
Description: CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB).~The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion).
Study: NCT05107115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: Tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablet, oral use
Study: NCT05257967

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar puncture and Phlebotomy
Description: Sampling of cerebral spinal fluid and plasma.
Study: NCT05125445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implants placed at bone crest
Description: Mid crestal incision will be performed and full-thickness envelope flap will be elevated to expose the alveolar ridge (no releasing incisions will be made).~Implant site will be prepared according to the manufacturer's instructions under sterile copious irrigation Implants will be placed at crestal level

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants placed 1mm Subcrestally
Description: Implants will be placed 1mm subcrestally
Study: NCT05303259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 2.5mg/kg, q2w, 4 cycles.
Study: NCT04949542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bolster
Description: Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
Study: NCT05474001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 10mg bubivacain intrathecal ( 2ml ) with 20microgram intrathecal fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: 10mg bubivacain intrathecal (2ml) with 0.5 ml saline with no intrathecal fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous graniseton
Description: 10mg bubivacain intrathecal ( 2ml ) with 0.5 ml saline with no intrathecal fentanyl with 1mg iv granisetron
Study: NCT05896423

Intervention type: BEHAVIORAL
Intervention: PrEP awareness materials
Description: Community-designed PrEP awareness materials - developed in the formative portion of this study
Study: NCT06418945

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tinidazole oral microneedle patch
Description: Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.
Study: NCT06124469

Intervention type: DIAGNOSTIC_TEST
Intervention: US-guided fine needle aspiration (FNA)
Description: This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
Study: NCT05927688

Intervention type: BEHAVIORAL
Intervention: Therapeutic management following access by the physician to his patient's ePROs
Description: Therapeutic management following access by the physician to his patient's ePROs

Intervention type: BEHAVIORAL
Intervention: Therapeutic management following access by the physician to his patient's ePROs
Description: Therapeutic management following access by the physician to his patient's ePROs
Study: NCT04830280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior quadratus lumborum block
Description: administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: posterior quadratus lumborum block
Description: administration local anesthetic solution between the middle layer of the thoracolumbar fascia and QL muscle at the posterior edge of the quadratus lumborum muscle
Study: NCT03505346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Study: NCT05901220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle
Description: An educational programme to promote healthy lifestyle will be performed.
Study: NCT05553717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 12.5mg\\12hr